A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia
- PMID: 34821021
- DOI: 10.1111/liv.15107
A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia
Abstract
Background: Hepatitis C virus (HCV) treatment through primary care and community-based services will be a critical component of HCV elimination. We evaluated a nurse-coordinated programme providing care across eight sites and analysed progression through the HCV care cascade.
Methods: People-accessing services from six primary care clinics, a homeless crisis accommodation provider and a mental health service were directly referred to nurses or engaged by nurses during regular clinic visits. Nurses supported HCV testing, treatment and follow-up. The prescription was provided by affiliated clinicians. Logistic regression was used to examine factors associated with treatment commencement and sustained virological response (SVR) testing.
Results: Of 640 people referred to and/or engaged by the nurses from January 2017 to July 2019, 518 had an HCV RNA test of whom 381 (74%) were HCV RNA positive. Treatment was commenced by 281 (74%) people of whom 161 had an SVR test, 157 (97.5%) were cured. Opioid agonist therapy was associated with treatment commencement (aOR 2.68, 95% CI 1.48-4.88). People who were homeless/unstably housed were less likely to commence treatment (aOR 0.45, 95% CI 0.23-0.87). Treatment prescription from a specialist (aOR 2.39, 95% CI 1.20-4.74) and recent injection drug use (<6 months) (aOR 2.15, 95% CI 1.07-4.31) was associated with SVR testing.
Conclusion: A nurse-coordinated model of care led to high levels of HCV treatment uptake and cure amongst people attending primary care and community services. More tailored models of care may be beneficial for people who are homeless or have unstable housing. These results support primary care and community-based hepatitis C treatment.
Keywords: hepatitis C; injection drug use; nurses; primary care.
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Comment in
-
Decentralisation of hepatitis C virus care into community settings: A key approach on the path to elimination.Liver Int. 2022 Jun;42(6):1222-1224. doi: 10.1111/liv.15229. Liver Int. 2022. PMID: 35678037 No abstract available.
References
REFERENCES
-
- Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192-e1207.
-
- Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030-what will it take to get there? J Int AIDS Soc. 2017;20(1):22146.
-
- Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(3 Suppl 1):112s-s121.
-
- Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350-1359.
-
- Muncan B, Walters SM, Ezell J, Ompad DC. “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical